| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 3.70 | 21.7% | 80.7% |
| Total Income | 3.70 | 21.7% | 80.7% |
| Expenditure | 68.57 | 11.6% | 25.2% |
| PBT | -64.14 | 32.4% | 269.5% |
| Net Profit | -64.14 | 32.4% | 269.5% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.52 | 30.0% | 246.7% |
NewAmsterdam Pharma Reports Q2 2026 Financial Results and Corporate Updates
05 Aug 2026 · 5 Aug, 4:42 pm
Summary
NewAmsterdam Pharma reported financial results for the second quarter ended June 30, 2026, alongside corporate updates. The company's revenue for the quarter was $3.7 million, a decrease from $19.1 million in the prior year's second quarter, primarily due to changes in revenue recognition from a license agreement. Research and Development expenses rose to $41.7 million from $27.5 million year-over-year, driven by clinical trial progression. The net loss widened to $64.1 million from $17.4 million in the same period last year. The company highlighted a positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe in Europe and maintained a strong cash position of $678.3 million.
Key Highlights
- 1
NewAmsterdam Pharma announced a positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe.
- 2
The company reported $678.3 million in cash, cash equivalents and marketable securities as of June 30, 2026.
- 3
Revenue for the quarter ended June 30, 2026 was $3.7 million, compared to $19.1 million in the same period in 2025.
- 4
Research and Development expenses increased to $41.7 million in Q2 2026 from $27.5 million in Q2 2025.
- 5
Net loss for the quarter ended June 30, 2026, was $64.1 million, compared to a net loss of $17.4 million for the same period in 2025.
- 6
Topline data from the RUBENS Phase 3 trial is expected by year-end 2026.
- 7
An interim analysis of the PREVAIL Phase 3 trial is planned for Q4 2026, with results expected in Q1 2027.
Management Comments
Michael Davidson
During the second quarter, we continued to build momentum across our regulatory, clinical, and scientific priorities. Our quarterly update is headlined by the positive opinion for Europe from CHMP, recommending the granting of a marketing authorization for Ubeslo and Evlarco, intended for the treatment of primary hypercholesterolemia or mixed dyslipidemia. Additionally, supportive analyses presented at NLA and AAIC continue to expand the growing body of evidence supporting the potential of obicetrapib across multiple diseases. As we continue to advance our late-stage development program and prepare for several important regulatory and clinical milestones in the months ahead, we remain focused on disciplined execution and look forward to sharing additional updates on our strategy, pipeline, and priorities during today’s Investor Day.
Informational and educational content only. Not investment advice.